TrialInternational immunopharmacology2021

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.

Masoud Solaymani-Dodaran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.